Rapport Therapeutics, Inc.

Rapport Therapeutics' RAP-219 Shows Promise in Phase 1 Trials for CNS Disorders

5 months ago

• Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders. • The Phase 1 trials demonstrated a favorable tolerability profile for RAP-219, with no serious adverse events reported in healthy volunteers. • RAP-219 selectively targets TARPγ8-associated AMPA receptors, potentially enhancing the therapeutic index for AMPA receptor modulation. • A Phase 2a trial of RAP-219 in focal epilepsy is ongoing, with topline data expected in mid-2025, according to Rapport Therapeutics.

Rapport Therapeutics Gains Buy Recommendation Based on RAP Platform and RAP-219 Potential

7 months ago

• Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders. • RAP-219, Rapport's lead candidate, shows promise for treating epilepsy, pain, and bipolar disorder by targeting TARPγ8, with Phase II trials planned for 2025. • Integration of NeuroPace's RNS device could enhance clinical proof of concept for RAP-219, improving patient recruitment and trial outcomes. • Strategic focus on selective targeting aims to minimize side effects, potentially positioning RAP-219 as a best-in-class treatment.